Circassia Group Plc (82C) - Total Liabilities
Based on the latest financial reports, Circassia Group Plc (82C) has total liabilities worth €8.60 Million EUR as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Circassia Group Plc - Total Liabilities Trend (2015–2025)
This chart illustrates how Circassia Group Plc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Circassia Group Plc Competitors by Total Liabilities
The table below lists competitors of Circassia Group Plc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sampo Corp
TW:1604
|
Taiwan | NT$9.46 Billion |
|
China General Plastics Corp
TW:1305
|
Taiwan | NT$9.19 Billion |
|
Suzhou Iron Technology Co. Ltd. A
SHG:688329
|
China | CN¥591.31 Million |
|
Hudson Technologies Inc
NASDAQ:HDSN
|
USA | $73.06 Million |
|
Jiin Yeeh Ding Enterprise Co Ltd
TWO:8390
|
Taiwan | NT$617.22 Million |
|
Kangstem Biotech Co. Ltd
KQ:217730
|
Korea | ₩11.60 Billion |
|
Oncoclinicas do Brasil
SA:ONCO3
|
Brazil | R$7.02 Billion |
|
RMR Group Inc
NASDAQ:RMR
|
USA | $272.28 Million |
Liability Composition Analysis (2015–2025)
This chart breaks down Circassia Group Plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.81 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Circassia Group Plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Circassia Group Plc (2015–2025)
The table below shows the annual total liabilities of Circassia Group Plc from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €8.60 Million | -3.37% |
| 2024-12-31 | €8.90 Million | +15.58% |
| 2023-12-31 | €7.70 Million | -53.61% |
| 2022-12-31 | €16.60 Million | -15.31% |
| 2021-12-31 | €19.60 Million | -47.03% |
| 2020-12-31 | €37.00 Million | -77.16% |
| 2019-12-31 | €162.00 Million | -10.74% |
| 2018-12-31 | €181.50 Million | +2.20% |
| 2017-12-31 | €177.60 Million | +232.58% |
| 2016-12-31 | €53.40 Million | -32.83% |
| 2015-12-31 | €79.50 Million | -- |
About Circassia Group Plc
NIOX Group Plc engages in the design, development, and commercialization of medical devices for asthma diagnosis, monitoring, and management worldwide. It offers NIOX VERO, a non-invasive and point-of-care system that comprises a small portable device and a range of consumables, including sensors, individual disposable mouthpieces, and breathing handles for the measurement of Fractional Exhaled N… Read more